USPTO Issues Inter Partes Reexamination Certificate of Key LNA Patent
- Santaris Pharma A/S
Sterne Kessler client Santaris Pharma A/S announces that it the USPTO has issued an Inter Partes Reexamination Certificate for U.S. Pat. No. 6,770,748 (the '748 patent). The certificate confirms the patentability of four original claims, one amended claim, and five new claims added by Santaris during the proceeding.
The '748 patent is a continuation-in-part of U.S. Pat. No. 6,268,490 (the 'Imanishi Patent), which was previously subject to an ex parte reexamination request brought by Isis Pharmaceuticals. Following this request, the USPTO issued an Ex Parte Reexamination Certificate confirming the patentability of all the original claims. The 'Imanishi and '748 patents claim rights to the Locked Nucleic Acid (LNA) or Bicyclic Nucleic Acid (BNA) chemical structure used for developing antisense molecules.
The Santaris Pharma A/S patent reexamination team is led by Eric K. Steffe and John M. Covert of Sterne, Kessler, Goldstein & Fox, P.L.L.C.